Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease [Yahoo! Finance]
CNBC's UK Exchange newsletter: The battle for Britain's investment trusts [CNBC]
Janus Henderson to Report Fourth Quarter and Full-Year 2025 Results [Yahoo! Finance]
Janus Henderson to Report Fourth Quarter and Full-Year 2025 Results
Andreessen Horowitz's shiny, new $15 billion reveals where the firm sees the biggest opportunities [Fortune]